Related Experiment Video
Updated: Jul 22, 2025

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
The sub-molecular characterization identification for cervical cancer
XinKai Mo1, Na Wang2, Zanjing He2
1Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, Shandong, PR China.
Background:
The efficacy of therapy in cervical cancer (CESC) is blocked by high molecular heterogeneity. Thus, the sub-molecular characterization remains primarily explored for personalizing the treatment of CESC patients.
Methods:
Datasets with 741 CESC patients were obtained from TCGA and GEO databases. The NMF algorithm, random forest algorithm, and multivariate Cox analysis were utilized to construct a classifier for defining the sub-molecular characterization. Then, the biological characteristics, genomic variations, prognosis, and immune landscape in molecular subtypes were explored. The significance of classifier genes was validated by quantitative Real-Time PCR, cell transfection, cell colony formation assay, wound healing assay, cell proliferation assay, and Western blot.
Results:
The CESC patients were classified into two subtypes, and the high classifier-score patients with significant differences in ECM-receptor interaction, PI3K-Akt signaling pathway, and MAPK signaling pathway showed a poorer prognosis in OS (p < 0.001), DFI (p = 0.016), PFI (p < 0.001) and DSS (p < 0.001), and with high the M0 Macrophage and resting Mast cells infiltration and low HLA family gene expression. Moreover, the constructed classifier owns a high identified accuracy in the tumor/normal groups (AUC: 0.993), the tumor/CIN1-CIN3 groups (AUC: 0.963), and normal/CIN1-CIN3 groups (AUC: 0.962), and the total prediction performance is better than currently published signatures in CESC (C-index: 0,763). The combined prediction performance further indicated that Nomogram (AUC = 0.837) is superior to the classifier (AUC = 0.835) and Stage (AUC = 0.568), and the C-index of calibration curves is 0.784. The potential biological function of classifier genes indicated that silencing GALNT2 inhibited the cancer cell's proliferation, migration, and colony formation; Conversely, the cancer cell's proliferation, migration, and colony formation were increased after the upregulation of GALNT2. The Epithelial-Mesenchymal Transition Experiment showed that GALNT2 knockdown might reduce the levels of Snail and Vimentin proteins and increase E-cadherin; Conversely, the levels of Snail and Vimentin proteins were increased, E-cadherin was reduced by GALNT2 upregulation.
Conclusion:
The classifier we constructed may help improve our understanding of subtype characteristics and provide a new strategy for developing CESC therapeutics. Remarkably, GALNT2 may be an option to directly target drivers in CESC cancer therapy.
Insights
This study identified two molecular subtypes of cervical cancer (CESC) with distinct prognoses. A novel classifier accurately distinguishes subtypes and highlights GALNT2 as a potential therapeutic target for CESC.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Cervical cancer (CESC) treatment efficacy is limited by molecular heterogeneity.
- Sub-molecular characterization is crucial for personalized CESC treatment strategies.
Purpose of the Study:
- To classify CESC patients into molecular subtypes.
- To develop a classifier for sub-molecular characterization.
- To explore the biological and prognostic implications of these subtypes.
Main Methods:
- Utilized NMF, random forest, and Cox analysis on TCGA and GEO datasets (741 CESC patients).
- Validated classifier gene significance using molecular and cellular assays (qPCR, Western blot, proliferation, migration assays).
Main Results:
- Identified two CESC subtypes; one associated with poorer prognosis, altered signaling pathways (ECM-receptor, PI3K-Akt, MAPK), immune cell infiltration (M0 Macrophage, resting Mast cells), and low HLA gene expression.
- Developed a highly accurate classifier (AUC > 0.96) outperforming existing CESC signatures.
- Demonstrated GALNT2's role in proliferation, migration, and epithelial-mesenchymal transition, suggesting it as a therapeutic target.
Conclusions:
- The constructed classifier enhances understanding of CESC subtypes and offers a new therapeutic strategy.
- GALNT2 emerges as a potential direct therapeutic target for cervical cancer.
More Related Videos
10:26RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
Published on: March 11, 2014
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019